OmniSeq receives New York State CLEP approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program approval for its OmniSeq Comprehensive panel, a 144 gene, pan-cancer, next-generation sequencing tumor profiling diagnostic panel to guide oncology treatment decision-making.

“OmniSeq is proud to receive New York State CLEP approval for OmniSeq Comprehensive. CLEP is the highest standard of Clinical Laboratory Improvement Amendments laboratory validation,” said Carl Morrison, president and chief scientific officer of OmniSeq and executive director of the Roswell Park Center for Personalized Medicine.

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login